SLC5A2 and chronic kidney disease: The ‘over-representation’ of patients with more advanced kidney disease in the DAPA-CKD and EMPA-KIDNEY trials was intended to determine whether the SGLT2 inhibitor benefits observed in previous trials extended to those with lower eGFR.